JP2006514067A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514067A5
JP2006514067A5 JP2004566589A JP2004566589A JP2006514067A5 JP 2006514067 A5 JP2006514067 A5 JP 2006514067A5 JP 2004566589 A JP2004566589 A JP 2004566589A JP 2004566589 A JP2004566589 A JP 2004566589A JP 2006514067 A5 JP2006514067 A5 JP 2006514067A5
Authority
JP
Japan
Prior art keywords
dosage form
safe dosage
pharmaceutically safe
forms
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004566589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514067A (ja
Filing date
Publication date
Priority claimed from US10/339,977 external-priority patent/US7524515B2/en
Application filed filed Critical
Publication of JP2006514067A publication Critical patent/JP2006514067A/ja
Publication of JP2006514067A5 publication Critical patent/JP2006514067A5/ja
Pending legal-status Critical Current

Links

JP2004566589A 2003-01-10 2003-12-18 製薬学的安全投薬形態物 Pending JP2006514067A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/339,977 US7524515B2 (en) 2003-01-10 2003-01-10 Pharmaceutical safety dosage forms
PCT/US2003/040990 WO2004062642A1 (en) 2003-01-10 2003-12-18 Pharmaceutical safety dosage forms

Publications (2)

Publication Number Publication Date
JP2006514067A JP2006514067A (ja) 2006-04-27
JP2006514067A5 true JP2006514067A5 (https=) 2007-02-08

Family

ID=23331375

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004566589A Pending JP2006514067A (ja) 2003-01-10 2003-12-18 製薬学的安全投薬形態物

Country Status (7)

Country Link
US (2) US7524515B2 (https=)
EP (1) EP1581188A4 (https=)
JP (1) JP2006514067A (https=)
AU (1) AU2003299826A1 (https=)
CA (2) CA2505661C (https=)
TW (1) TWI265812B (https=)
WO (1) WO2004062642A1 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229705B1 (en) 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
JP2005515966A (ja) * 2001-07-06 2005-06-02 エンドー ファーマシューティカルズ， インコーポレイティド 鎮痛薬としての使用のための６−ヒドロキシ−オキシモルホンの経口投与
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
DE60223254T2 (de) * 2001-07-06 2008-08-14 Penwest Pharmaceuticals Co. Verzögert freisetzende formulierungen von oxymorphon
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
AU2002337686B2 (en) * 2001-09-26 2008-05-15 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
ES2665464T3 (es) * 2003-03-28 2018-04-25 Sigmoid Pharma Limited Forma de dosificación oral sólida que contiene microcápsulas sin costuras
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
EP1648425B1 (en) * 2003-07-30 2007-02-21 Merrion Research I Limited Process and Machine for the Automated Manufacture of Gastro-Retentive Capsules
EP1660048A4 (en) * 2003-08-12 2009-07-08 Endo Pharmaceuticals Inc PROCESS FOR PREVENTING OPIOID ABUSE BY COMBINING WITH NON-RELEASABLE EMETIC FORMULATION
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
AU2013206525B2 (en) * 2003-11-26 2015-09-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
PT1718258E (pt) * 2004-02-23 2009-06-16 Euro Celtique Sa Dispositivo de administração transdérmica de opióides com resistência ao abuso
CA2916869A1 (en) 2004-06-12 2005-12-29 Jane C. Hirsh Abuse-deterrent drug formulations
EP1773376A4 (en) * 2004-08-03 2009-07-01 Emisphere Tech Inc ANTIDIBLE ORAL INSULIN BIGUANIDE COMBINATION
US7226619B1 (en) 2004-09-07 2007-06-05 Pharmorx Inc. Material for controlling diversion of medications
EP1802287A2 (en) * 2004-09-27 2007-07-04 Sigmoid Biotechnologies Limited Minicapsule formulations
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070231268A1 (en) * 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060110327A1 (en) * 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US9060950B2 (en) * 2005-06-13 2015-06-23 Paul H. Rosenberg, Proximate Concepts, LLC. Emetic embedded capsule
JP2008543851A (ja) * 2005-06-13 2008-12-04 ポール・ローゼンバーグ 催吐剤封入カプセル
DE102006006532B4 (de) * 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
ES2439581T3 (es) * 2006-12-04 2014-01-23 Orexo Ab Nueva composición farmacéutica no susceptible de abuso que comprende opioides
ES2393814T3 (es) 2007-04-04 2012-12-28 Sigmoid Pharma Limited Una composición farmacéutica oral
CA2685118C (en) * 2007-04-26 2016-11-01 Sigmoid Pharma Limited Manufacture of multiple minicapsules
WO2008132712A2 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Combination pharmaceutical compositions
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US20130079749A1 (en) * 2007-08-29 2013-03-28 Advanced Bionics, Llc Modular Drug Delivery System for Minimizing Trauma During and After Insertion of a Cochlear Lead
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
JP2011515495A (ja) * 2008-03-26 2011-05-19 オールトランツ インコーポレイティド オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑制経皮製剤
GB0817969D0 (en) * 2008-10-01 2008-11-05 Axcess Ltd Pharmaceutical composition
WO2010066034A1 (en) * 2008-12-12 2010-06-17 Paladin Labs Inc. Methadone formulation
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
CN102573802A (zh) 2009-08-12 2012-07-11 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
AU2010300641B2 (en) * 2009-09-30 2016-03-17 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
ME02874B (me) 2010-12-22 2018-04-20 Purdue Pharma Lp Obloženi dozni oblici sa kontrolisanim oslobađanjem otporni na zloupotrebu
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
JP6210988B2 (ja) 2011-09-19 2017-10-11 オレクソ・アクチエボラゲット オピオイド依存を治療するための新規乱用耐性医薬組成物
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
MX366159B (es) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
WO2015145461A1 (en) 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
JP6716582B2 (ja) 2014-11-07 2020-07-01 サブリミティ・セラピューティクス・リミテッドＳｕｂｌｉｍｉｔｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ シクロスポリンを含む組成物
AU2016259861B2 (en) * 2015-05-13 2020-08-13 4P-Pharma Stimulant abuse-deterrent compositions
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
TWI857302B (zh) * 2021-05-28 2024-10-01 大陸商上海雲晟研新生物科技有限公司 硝苯地平美托洛爾緩釋組合物、其製備方法及應用
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6091A (en) * 1849-02-06 Improvement in rotary-cutter plows
US35839A (en) * 1862-07-08 Improvement in vegetable-cutters
GB1428361A (en) 1972-02-15 1976-03-17 Grant A Safeguarded medicinal compositions
US4175119A (en) * 1978-01-11 1979-11-20 Porter Garry L Composition and method to prevent accidental and intentional overdosage with psychoactive drugs
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4371539A (en) * 1981-04-27 1983-02-01 American Home Products Corporation CNS Stimulants
US4459278A (en) * 1983-03-07 1984-07-10 Clear Lake Development Group Composition and method of immobilizing emetics and method of treating human beings with emetics
US4529583A (en) * 1983-03-07 1985-07-16 Clear Lake Development Group Composition and method of immobilizing emetics and method of treating human beings with emetics
GB2162061B (en) 1984-05-03 1988-11-16 Bibhuti B Bardhan Controlled time release therapeutic composition having means for counteracting overdosage
US4885173A (en) * 1985-05-01 1989-12-05 University Of Utah Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4981468A (en) * 1989-02-17 1991-01-01 Eli Lilly And Company Delivery device for orally administered therapeutic agents
US5547878A (en) * 1993-11-02 1996-08-20 Kell; Michael Method of monitoring patient compliance with medications prescriptions
US5856493A (en) * 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
WO1998002186A1 (en) * 1996-07-11 1998-01-22 Farmarc Nederland B.V. Inclusion complex containing indole selective serotonin agonist
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
GB9710726D0 (en) * 1997-05-23 1997-07-16 Nycomed Imaging As Compound
CA2261787C (en) * 1997-05-30 2006-11-14 Laboratorios Phoenix U.S.A., Inc. Multi-layered osmotic device
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CA2314896C (en) * 1997-12-22 2005-09-13 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
ES2138937B1 (es) * 1998-07-07 2000-10-01 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
HU229705B1 (en) 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
GB0026137D0 (en) 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
JP2005515960A (ja) * 2001-05-11 2005-06-02 エンドー ファーマシューティカルズ， インコーポレイティド 乱用耐性のオピオイド投薬形態
US20030035839A1 (en) 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
SI1416842T1 (sl) 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
AU2002324624A1 (en) 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7141250B2 (en) * 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
EP1450824A4 (en) * 2001-11-02 2005-09-28 Elan Corp Plc PHARMACEUTICAL COMPOSITION
US20040126428A1 (en) 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
US6472563B1 (en) * 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
SI1530469T1 (sl) 2002-08-20 2009-06-30 Euro Celtique Sa Transdermalna odmerna oblika, ki obsega aktivno sredstvo in antagonist v obliki soli in v obliki proste baze
DE10250084A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms

Similar Documents

Publication Publication Date Title
JP2006514067A5 (https=)
CA2505661A1 (en) Pharmaceutical safety dosage forms
US12582647B2 (en) Systems and methods for treating an opioid-induced adverse pharmacodynamic response
RU2011121513A (ru) Новые и эффективные лекарственные формы тапентадола
US8883817B2 (en) Combination analgesic employing opioid and neutral antagonist
US20080176885A1 (en) Novel synergistic opioid-cannabinoid codrug for pain management
RU2000101024A (ru) Опоидные анальгетики с контролируемым высвобождением активных веществ
CN101022787A (zh) 防滥用的含有（1r，2r）－3－（3－二甲氨基－1－乙基－2－甲基－丙基）苯酚的口服剂型
US20180193331A1 (en) Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response
US20160120861A1 (en) Compositions and Methods for Treating an Arrhythmia with an Opioid Antagonist
US7404970B2 (en) Pain relief composition, method to form same, and method to use same